OUR LATEST UPDATE: Biocoat Secures New Patent for Non-PFAS Inner Diameter Coating… READ MORE
OUR LATEST UPDATE: Biocoat Secures New Patent for Non-PFAS Inner Diameter Coating… READ MORE
We are a global leader in the development, manufacturing and application of hydrophilic (slippery) coatings used in medical devices. Our hydrophilic coatings allow for medical devices to easily traverse through the body by minimizing friction as the material moves to its intended destination. Our custom hydrophilic coatings are lubricious, abrasion resistant, biocompatible and can be applied to a wide range of polymeric and metallic substrates.
Biocoat headquarters are located in Horsham, PA, about 45 minutes outside of Philadelphia, PA. In May 2018, Biocoat officially opened our new facility at Rock Road, bringing our total square footage to 46,000 square feet. Biocoat has six ISO 7 cleanrooms, manufacturing, R&D and disaster recovery facilities all dedicated to the development and expert application of our hydrophilic coatings.
Our Application Development team consists of Scientists and Engineers who support the development of our coatings for the device requiring the hydrophilic coating.
Our Application Development technical team:
The strength of an organization lies in its people. The team of experts at Biocoat, and its Board of Directors, is made up of leaders in the industry, clinical champions and innovative thinkers.
Jim Moran
President & CEO
Scott D’Amour
Chief Financial Officer
Robert Hergenrother, PhD
Vice President, Research, Development and Innovation
Thomas Brugnoli
Vice President, Operations
Heather L.A. Hennessey
Senior Director, Quality Assurance & Regulatory Affairs
Acquired Denmark-based polymer company, Chempilots
Biocoat introduces EMERSE Dip Coating System our new hydrophilic dip coating equipment line
Biocoat introduces a new UV cured version of our HYDAK coatings.
To read more about our Coating Services, visit our Custom Coating Solutions section in the main navigation.
Biocoat receives its ISO 13485:2016 certification.
Biocoat celebrates its renewed mission to offer industry-leading custom coating solutions with its acquisition by 1315 Capital.
The Rock Road facility opens, bringing the company’s total square footage to over 62,000 square feet.
Biocoat undergoes a complete rebranding, better reflecting the cutting-edge technology they offer their medical device partners.
Construction of Biocoat state-of-the-art Rock Road headquarters begins in Horsham, PA. The new facility, in combination with the original Witmer Road facility, means over 62,000 square feet of production capacity.
Biocoat releases the revolutionary PICSI® Sperm Selection Device.
Biocoat headquarters officially moves from Beaver College to its new home on Witmer Road in Horsham, PA.
Biocoat proprietary Hyaluronan Binding Assay (HBA) is released to the medical device market.
Ellington Beavers, visionary and founder of Biocoat, retires.
Two companies license Biocoat products for commercial use.
By Ellington Beavers at Beaver College (present day Arcadia University)
The latest news, articles, and resources, sent to your inbox.
Global Vice President, Sales
Greg Santorno is the Biocoat Vice President of Sales and Marketing. In this role, Greg leads the Sales and Marketing teams with the collective mission of serving current and new customers with superior customer support and industry-leading coating performance.
Greg joined Biocoat after spending more than 20 years serving the medical device industry while working at Viant Medical as the Vice President of Global Accounts and at Integer Holdings Corporation (formerly Lake Region Medical, Accellent, and MedSource Technologies), where he held various commercial, operations and functional leadership roles. Prior to joining Integer, Greg held business development, operations, and program management roles in multiple manufacturing organizations, including Lockheed Martin.
Greg received a Bachelor of Science degree from Colorado State University.
Controller
Senior Director of Marketing
Director, Human Resources
Thomas (Tommy) Cataldi is the Director of Human Resources for Biocoat. In his role, he is responsible for oversight of the “people” side of our business, which includes all HR administrative functions.
Tommy joined Biocoat in 2021 with over 20 years of experience in HR and 11+ years leading an HR department. He has a history of achievement of building HR from the ground up in U.S. and non-U.S. locations, along with proven success integrating employees after M&As. His background includes work at multi-international companies and companies that specialize in engineering and/or sciences.
Tommy received a Bachelor of Arts in English Literature from West Chester University, a Master of Business Administration (MBA) from Clemson University and HR Certification from Villanova University. He received his Senior Professional in Human Resources (SPHR) designation in 2003.
Director, Business Development
Joshua de Freitas is the Biocoat Director of Business Development for Coating Products and Services. In this role, Josh is responsible for guiding Biocoat’s customers in coating design, development, and commercialization.
Josh joined Biocoat in 2020 after spending nearly 10 years in leadership and commercial positions supporting the medical device industry with roles at TE Connectivity and DSM Biomedical. Josh started his professional career serving 11 years as a US Army Officer and Medical Evacuation Helicopter Pilot with assignments around the globe.
Senior Director, Business Development, Coating Equipment
Dhruv Patel is the Senior Director of Business Development, Coating Equipment for Biocoat. In this role, Dhruv is responsible for leading Biocoat customers in the design, development, and hydrophilic coating equipment.
Dhruv joined Biocoat in 2009 and holds a Bachelor of Science degree from the University of Mumbai, and two Masters degrees, one in Biomedical Engineering from the New Jersey Institute of Technology and the other in Business Administration from Villanova University.
President & CEO, Biocoat
Jim Moran is the President and CEO of Biocoat, Inc, a position he has held since 2018. Jim has been in the medical industry for over 25 years in various leadership, sales and marketing roles in both domestic and international assignments. Prior to joining Biocoat, he worked at Bracco Diagnostics, Acclarent, ConvaTec, TaylorMade-adidas Golf, Songbird Hearing and Vistakon. Jim also founded his own privately held medical device company called Jazz Medical in 2012 to provide advanced wound care products to the veterinary market.
Jim received a Master of Business Administration from the University of Phoenix and a Bachelor of Science in Marketing from St. Joseph’s University in Philadelphia.
President and CEO, Palvella Therapeutics
Wes Kaupinen has been on the Biocoat Board since 2017 and is the President and CEO of Palvella Therapeutics. Wes has an extensive background in M&A, business development, and capital raising, having spent time an as investment banker, venture capital investor and senior executive at a publicly traded life sciences company. Wes has extensive networks in the cardiovascular, neurovascular, peripheral vascular, ophthalmic markets as well as in the private equity arena.
Wes has an MBA degree from the Wharton School at University of Pennsylvania and a B.A. from the University of Virginia.
SVP, Commercial & Strategy, Surgical Specialties Corporation
Matt has held senior level positions within multi-national and emerging growth medical device & diagnostics companies. His experience spans corporate development, strategic planning, sales, marketing, finance, and general management leadership roles for branded products and contract manufacturing businesses.
Currently, he is Senior Vice President, Commercial & Strategy for Surgical Specialties Corporation. Previously, Matt held various positions with Accriva Diagnostics, Covidien, Flex, and Accellent.
Matt earned an MBA from the Kellogg School of Management at Northwestern University, and a Bachelor of Science degree in Business from Georgetown University.
Founding Partner, 1315 Capital
Michael Koby co-founded 1315 Capital in 2014, after spending his entire career as a healthcare investor and operator, including experience with more than 25 growth equity investments. Prior to founding 1315 Capital, Michael was a Managing Director at Palm Ventures, a private-equity focused family office where he led all healthcare investing. While at Palm, Michael led investments in Enigma Diagnostics, Axcentria Pharmaceuticals, and JDS Therapeutics. He currently serves on the boards of Biocoat, Centurion Service Group, CHC Solutions, JDS Therapeutics, and Solsys Medical.
Before Palm Ventures, Michael spent over a decade as an investor, including before and after business school, at Galen Partners, a healthcare growth equity investment firm. He also held business development roles at Novoste Corporation and Medtronic, Inc. Michael started his career as a healthcare investment banking analyst at Dillon, Read & Co.
Michael received a BSc from Cornell University and an MBA in Healthcare Management from The Wharton School.
Chairman of the Board President & CEO, DNA Diagnostics Center
Scott has over 30 years’ experience and is a proven and focused medical device & diagnostics CEO. He has significant experience driving change by instilling a culture of high performance and implementing growth strategies as well as operational improvement initiatives, resulting in a track-record of successful exits.
Scott has served in executive level positions at Accriva Diagnostics, Warburg Pincus, Novasys Medical, Bacchus Vascular, VNUS Medical, EndoSonics (Volcano Corporation), Cardiometrics and Baxter Healthcare Corporation.
Scott holds a B.S. degree in Finance from Philadelphia University.
Senior Director, Quality Assurance & Regulatory Affairs
Heather L.A. Hennessey is the Biocoat Senior Director of Quality Assurance & Regulatory Affairs, and Management Representative for Biocoat. In her role, Heather is responsible for oversight of the Quality Assurance and Quality Control groups, as well as ensuring overall quality and regulatory compliance for the entire organization.
Heather joined Biocoat in 2020 and has a 20 year track record of success in compliance remediation, driving out inefficiencies, and implementing change and continuous improvement at such companies as Polysciences, Regeneron, The Secant Group, Cenveo, AstraZeneca (Medimmune), and Day & Zimmermann International.
Heather received a Bachelor of Science in Biology from Stockton University and is a certified ISO 13485:2016 Lead Auditor.
Vice President, Business Development
Joe Sandora joined Biocoat in 2018 as Vice President of Business Development. In his role, Joe has been responsible for all domestic and international strategic relationships, contract negotiations and corporate sales strategy.
He has over 25 years in business development and senior sales management in the medical device industry having previously been with Devon Medical Products, Georgia-Pacific Professional, and ConvaTec- A Bristol Myers Squibb Company.
Joe holds a Bachelor of Arts degree from St. Lawrence University.
Vice President of Operations
Thomas (Tom) Brugnoli is the Biocoat Vice President of Operations. Tom joined Biocoat in 2019 to lead the design and management of the Contract Coating Services unit. Tom is also responsible for the manufacturing of all coating reagents.
Tom has over 30 years of manufacturing experience which he obtained from prior operations, manufacturing and engineering services positions at Bristol-Myers Squibb and ConvaTec.
Vice President, Research, Development and Innovation
Dr. Robert (Bob) Hergenrother is the Biocoat Vice President of Research, Development and Innovation. In this role, Bob leads the research team in the development, maximization and exploration of new products and coating methodologies.
Bob joined Biocoat in 2017 after spending nearly 25 years in research and development roles at the Southern Research Institute, Surmodics and Boston Scientific. Bob was also a Professor in the Department of Biomedical Engineering at the University of Alabama at Birmingham.
Bob holds a Bachelor of Science degree from the University of Notre Dame and a PhD in Chemical Engineering from the University of Wisconsin-Madison.
Chief Financial Officer
Scott is the Biocoat Chief Financial Officer. As CFO, Scott provides executive oversight of Biocoat’s financial and technology functions. Scott joined Biocoat in 2023 and brings over 30 years of financial experience with leadership roles in the life sciences, medical technology, and technology industries. Scott’s experience includes working at Leidos, Berkshire Grey, Medtronic, HeartWare, Biotage, Bioprocessors, and Applied Biosystems.
Scott received his Bachelor of Science in Management from the University of Massachusetts Lowell and his Master of Business Administration and Master of Science in Finance from Boston College’s Carroll Graduate School of Management.
President & CEO
Jim Moran is the President and CEO of Biocoat Incorporated, a position he has held since 2018. Jim has been in the medical industry for over 25 years in various leadership, sales and marketing roles in both domestic and international assignments. Prior to joining Biocoat, he worked at Bracco Diagnostics, Acclarent, ConvaTec, TaylorMade-adidas Golf, Songbird Hearing and Vistakon. Jim also founded his own privately held medical device company called Jazz Medical in 2012 to provide advanced wound care products to the veterinary market.
Jim received a Master of Business Administration from the University of Phoenix and a Bachelor of Science in Marketing from St. Joseph’s University in Philadelphia.
16527